ALLMedicine™ Ewing Sarcoma Center
Research & Reviews 1,174 results
https://doi.org/10.2174/1574888X17666220627114710
Current Stem Cell Research & Therapy; Dos Santos RP, Gregianin L et. al.
Jun 29th, 2022 - Resistance to chemotherapy poses a major challenge for cancer treatment. Reactivation of a stem cell program resembling that seen in embryonic development can lead cancer cells to acquire a stem-cell phenotype characterized by expression of stemne...
https://clinicaltrials.gov/ct2/show/NCT01804634
Jun 24th, 2022 - Allogeneic hematopoietic stem cell transplantation (HSCT) may be associated with a clinically significant "graft-versus-tumor" (GVT) effect, even against disease that is unresponsive to chemotherapy and radiation therapy. Graft-vs.-tumor (GVT) eff...
https://clinicaltrials.gov/ct2/show/NCT04890093
Jun 24th, 2022 - Background: Irinotecan is a prodrug of an inhibitor of topoisomerase 1 (active metabolite is SN-38) with known activity in sarcomas, however it has limitations including suboptimal bioavailability and systemic side effects including severe diarrhe...
https://doi.org/10.1038/s41388-022-02383-x 10.1038/s41572-018-0003-x 10.1038/359162a0 10.1093/nar/gki270 10.1128/MCB.18.3.1489 10.1172/JCI31222 10.1016/j.molcel.2007.11.015 10.1056/NEJMra0804615 10.1006/cimm.1995.1185 10.1016/S0092-8674(00)80086-0 10.1101/gad.1934210 10.1016/j.molcel.2011.05.035 10.1002/em.22397 10.1093/jmcb/mju045 10.1016/j.tibs.2009.12.003 10.1042/EBC20190095 10.1101/gad.2021311 10.1074/jbc.272.43.27369 10.1073/pnas.96.25.14300 10.1016/S0014-5793(00)01590-8 10.1046/j.1365-3083.1997.d01-447.x 10.1042/BJ20082097 10.1016/j.bbrc.2005.02.018 10.1111/j.1742-4658.2011.08020.x 10.1038/onc.2008.484 10.1126/science.8036511 10.1155/2013/642853 10.1016/j.jmb.2004.04.078 10.1074/jbc.M001661200 10.1038/nature00947 10.1016/j.cell.2005.01.028 10.1016/j.jid.2018.05.015 10.1007/s13238-011-1063-9 10.1128/MCB.01382-07 10.1007/s00018-017-2717-4 10.1074/jbc.M210479200 10.1074/jbc.M709707200 10.1128/MCB.01969-08 10.1016/j.febslet.2013.01.035 10.1016/j.cell.2009.03.010 10.1038/nsmb.1912 10.1038/35071124 10.1016/j.bbamcr.2010.01.005 10.1038/sj.onc.1207928 10.1038/s41419-020-2640-8 10.3389/fendo.2021.600682 10.1126/sciadv.abj8357 10.1146/annurev-biochem-060614-034325 10.1038/emboj.2011.106
Oncogene Zhang T, Wang Z et. al.
Jun 23rd, 2022 - Ewing sarcoma breakpoint region 1 (EWSR1) is a member of FET (FUS/EWSR1/TAF15) RNA-binding family of proteins. The Ewing sarcoma oncoprotein EWS-FLI1 has been extensively studied, while much less is known about EWSR1 itself, especially the potenti...
https://doi.org/10.1097/CCO.0000000000000855
Current Opinion in Oncology; Brahmi M, Vanacker H et. al.
Jun 23rd, 2022 - CIC-DUX4 sarcoma (CDS) is a high-grade undifferentiated round cells sarcoma that belongs to the undifferentiated round cell sarcomas family. It represents less than one percent of sarcomas, defining a rarest among rare malignancies. It affects you...
Guidelines 5 results
https://doi.org/10.1016/j.otsr.2018.12.015
Orthopaedics & Traumatology, Surgery & Research : OTSR; Gomez-Brouchet A, Mascard E et. al.
Apr 10th, 2019 - Standardized reports are essential to meeting the bone sarcoma reference center certification requirements of the French National Cancer Institute (INCa). The usual classifications of the Musculoskeletal Tumor Society (MSTS), the American Joint Co...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762797
Archives of Gynecology and Obstetrics; Schüring AN, Fehm T et. al.
Nov 28th, 2017 - Most guidelines about fertility preservation are predominantly focused on scientific evidence, but are less practically orientated. Therefore, practically oriented recommendations are needed to support the clinician in daily practice. A selective ...
https://doi.org/10.1093/annonc/mdu153
Annals of Oncology : Official Journal of the European Soc... Wilhelm M, Dirksen U et. al.
Jun 26th, 2014 - Teenagers and young adults (TYA) cancer contributes substantially to morbidity and mortality in a population with much to offer society. TYA place distinct challenges upon cancer care services, many reporting feeling marginalized and their needs n...
https://doi.org/10.1002/pbc.21596
Pediatric Blood & Cancer; Meyer JS, Nadel HR et. al.
May 6th, 2008 - The Children's Oncology Group (COG) is a multi-institutional cooperative group dedicated to childhood cancer research that has helped to increase the survival of children with cancer through clinical trials. These clinical trials include a standar...
https://www.cancer.gov/types/bone/hp/ewing-treatment-pdq?cid=eb_govdel
National Cancer Institute
Dramatic improvements in survival have been achieved for children and adolescents with cancer.[1] Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.[1] For Ewing sarcoma, the 5-year survival rate has increased from 59% t...
Drugs 8 results see all →
Clinicaltrials.gov 95 results
https://clinicaltrials.gov/ct2/show/NCT01804634
Jun 24th, 2022 - Allogeneic hematopoietic stem cell transplantation (HSCT) may be associated with a clinically significant "graft-versus-tumor" (GVT) effect, even against disease that is unresponsive to chemotherapy and radiation therapy. Graft-vs.-tumor (GVT) eff...
https://clinicaltrials.gov/ct2/show/NCT04890093
Jun 24th, 2022 - Background: Irinotecan is a prodrug of an inhibitor of topoisomerase 1 (active metabolite is SN-38) with known activity in sarcomas, however it has limitations including suboptimal bioavailability and systemic side effects including severe diarrhe...
https://clinicaltrials.gov/ct2/show/NCT02657005
Jun 22nd, 2022 - The study has been expanded to explore single agent TK216 for longer treatment duration. Approximately 26 patients will be enrolled in this Cohort.
https://clinicaltrials.gov/ct2/show/NCT05071209
Jun 10th, 2022 - PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of BAY 1895344 (elimusertib) administered as an oral tablet, twice per day for 3 days on and 4 days off to patients < 18 years of age with r...
https://clinicaltrials.gov/ct2/show/NCT04901702
Jun 9th, 2022 - ONITT (ONIvyde, Talazoparib, Temozolomide) is a phase I/II study which will evaluate two treatment regimens; nanoliposomal irinotecan (nal-IRN, Onivyde) plus talazoparib (TAL) and Onivyde (ONI) plus temozolomide (TMZ) for the treatment of recurren...
News 51 results
https://www.medscape.com/viewarticle/975065
Jun 5th, 2022 - High-dose ifosfamide has shown superior survival benefit over three other chemotherapy regimens for patients with recurring or refractory primary Ewing sarcoma (RR-ES) in the practice-changing rEECur trial. This international trial is the first ra...
https://www.onclive.com/view/devimistat-plus-hydroxychloroquine-shows-early-promise-in-relapsed-clear-cell-sarcoma
Jan 7th, 2022 - No dose-limiting toxicities (DLTs) have been reported in the first cohort of patients with relapsed clear cell sarcoma who received the combination of devimistat (CPI-613) and hydroxychloroquine in the dose-escalation portion of the ongoing phase ...
https://www.onclive.com/view/onct-216-shows-encouraging-efficacy-safety-in-relapsed-refractory-ewing-sarcoma
Nov 24th, 2021 - The targeted small molecule inhibitor of the E26 transformation-specific family of oncoproteins, ONCT-216 (formerly TK216), produced notable response and disease control rates when delivered at the recommended phase 2 dose (RP2D) to heavily pretre...
https://www.onclive.com/view/demetris-team-approach-translates-into-success-in-sarcoma-research
Oct 6th, 2021 - George D. Demetri, MD For some cancer researchers, success means running your own laboratory independent of others, who might be viewed as competitors. Others, like George D. Demetri, MD, find success pursuing a career as a translational and clin...
https://www.onclive.com/view/dr-federman-on-ongoing-research-in-rare-bone-and-soft-tissue-sarcoma
Oct 6th, 2021 - Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma. Current research at UCLA’s Jonnson Comprehensive Cancer Ce...
